Compare DRH & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DRH | PHVS |
|---|---|---|
| Founded | 2004 | 2015 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.4B |
| IPO Year | 2004 | 2020 |
| Metric | DRH | PHVS |
|---|---|---|
| Price | $12.72 | $37.10 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 10 | 11 |
| Target Price | $10.38 | ★ $41.82 |
| AVG Volume (30 Days) | ★ 2.6M | 618.6K |
| Earning Date | 04-30-2026 | 05-12-2026 |
| Dividend Yield | ★ 3.51% | N/A |
| EPS Growth | ★ 144.44 | N/A |
| EPS | ★ 0.51 | N/A |
| Revenue | ★ $1,120,491,000.00 | N/A |
| Revenue This Year | $3.44 | N/A |
| Revenue Next Year | $2.42 | N/A |
| P/E Ratio | $24.88 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.48 | $20.65 |
| 52 Week High | $13.79 | $38.13 |
| Indicator | DRH | PHVS |
|---|---|---|
| Relative Strength Index (RSI) | 53.87 | 59.27 |
| Support Level | $9.10 | $24.73 |
| Resistance Level | $13.79 | N/A |
| Average True Range (ATR) | 0.28 | 1.75 |
| MACD | 0.00 | 0.15 |
| Stochastic Oscillator | 77.55 | 77.78 |
Diamondrock Hospitality Company is a real estate investment trust that owns lodging properties. Its business is to acquire, own, manage, and renovate full-service hotel properties in the United States. It operates in cities such as Chicago, Boston, New York, Denver, and others. Within DiamondRock's holdings, the majority of the hotel brands include Marriott, Starwood, and Hilton. The company operates in one reportable segment: The hotel ownership segment, which is comprised of upper upscale and luxury chain scale hotels that offer hotel rooms, food and beverage and other ancillary guest services.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks. The company is also running open-label extension studies in both on-demand (RAPIDe-2) and prophylactic (CHAPTER-4) settings to collect long-term safety and efficacy data in HAE patients.